Skip to main content
Equibles

MARSHALL WACE, LLP

Position in ANIX — Anixa Biosciences Inc

CIK 1318757 LONDON, X0
Back to ANIX Full portfolio

Position in ANIX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$919,329
+$472,528 QoQ
Shares Held
328,332
+89.6% QoQ
Ownership
0.965%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#6
of 62 holders
Holding Since
Sep 2021
11 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in ANIX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. ANIX ranks #186 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 543,897 $270,169,956
2 INCY
Incyte Corp
 1,310,154 $148,519,056
3 RPRX
Royalty Pharma plc
 2,450,669 $137,409,009
4 SYRE
Spyre Therapeutics, Inc.
 991,693 $88,042,503
5 ALNY
Alnylam Pharmaceuticals, Inc.
 259,799 $78,207,292
6 TVTX
Travere Therapeutics, Inc.
 1,333,207 $75,739,488
7 MANE
Veradermics, Inc
 585,560 $71,988,746
8 DFTX
Definium Therapeutics, Inc.
 1,298,946 $61,102,419

All Filings in ANIX

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $919,329 328,332
2026-03-31 $446,801 173,179
2025-12-31 $126,540 40,558
2025-09-30 $206,965 62,717
2025-06-30 $38,682 11,722
2024-09-30 $140,121 44,483
2024-03-31 $82,280 26,372
2023-12-31 $41,419 10,675
2022-03-31 $79,249 28,923
2021-12-31 $124,659 41,973
2021-09-30 $200,211 41,973